Prostate cancer: The role of hormonal therapy

Journal of Experimental and Clinical Cancer Research

Volumn 24, Issue 2, 2005, Pages 175-180

  Salesi, N ^a   Carlini, Paolo ^a   Ruggeri, E M ^a   Ferretti, G ^a   Bria, E ^a   Cognetti, F ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Hormone therapy; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; GOSERELIN; TESTOSTERONE;

ADVANCED CANCER; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER STAGING; CAUSE OF DEATH; EARLY DIAGNOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; SURVIVAL RATE;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 22844435185     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Greenlee R.T., Hill-Harmon M.B., Murray T., Thun M.: Cancer statistics. CA Cancer J. Clin. 51: 15-36, 2001.
2. Zwergel U., Lehmann J., Wullich B. et al.: Lymph node positive prostate cancer: long-term survival data after radical prostatectomy. J. Urol. 171: 1128-1131, 2004.
3. Byar D.P.: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 32: 1126-1130, 1973.
4. Byar D.P., Cole D.K.: Hormone therapy for prostate cancer: Results of the Veterans' Administration Cooperative Urological Research Group studies. NCI Monogr 7: 165-170, 1988.
5. Messing E.M., Manola J., Sarosdy M., Wilding G., Crawford E.D., Trump D.: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N. Engl. J. Med. 9: 1781-1788, 1999.
6. Boccardo F.: Esiste una terapia adiuvante nell'early stage? I Supplementi di Tumori. Vol. 2, No 4, S150, 2003.
7. See W.A., Wirth M.P., McLeod D.G. et al.: Casodex Early Prostate Cancer Trialist Group. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. Urol. 168: 429-435, 2002.
8. See W., Iversen P., Wirth M., McLeod D., Garside L., Morris T.: Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. Eur. Urol. 44: 512-517; discussion 517-518, 2003.
9. Bolla M., Gonzalez D., Warde P. et al.: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med. 337: 295-300, 1997.
10. Bolla M., Collette L., Blank L. et al.: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 13: 103-106, 2002.
11. Pilepich M.V., Caplan R., Byhardt R.W. et al.: Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J. Clin. Oncol. 15: 1013-1021, 1997.
12. Pilepich M.V., Winter K., Lawton C. et al.: Phase III trial of androgen suppression adjuvant to definitive radiotherapy. Long term results of RTOG study 85-31 (abstract). Proc. Am. Soc. Clin. Oncol. 22: 1530, 2003.
13. Hanks G.E., Pajak T.F., Porter A. et al.: Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the radiation therapy oncology group protocol 92-02. J. Clin. Oncol. 21: 3972-3978, 2003.
14. Pansadoro V., Sternberg C.: Neo-adjuvant hormonal therapy and radical prostatectomy for locally advanced prostate cancer. Mol. Urol.: A Transl. Approach 3: 271-275, 1999.
15. Soloway M.S., Sharifi R., Wajsman Z., McLeod D., Wood D.P., Puras-Baez A.: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Luprot Depot Neoadjuvant Prostate Cancer Study Group. J. Urol. 154: 424-428, 1995.
16. Schulman C.C., Debruyne F.M.J., Forster G., Selvaggi P.P., Zlotta A.R., Witjes W.P.J.: 4-year follow-up results of a European Prospective Randomized Study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3NOMO prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur. Urol. 38: 706-713, 2000.
17. Zelefsky M.J., Wallner K.E., Ling C. et al.: Comparison of the 5 year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine 125 implantation for early stage prostatic cancer. J. Clin. Oncol. 17: 517-522, 1999.
18. Forman J.D., Kumar R., Haas G. et al.: Neoadjuvant hormonal downsizing of localised carcinoma of the prostate: effects on the volume of normal tissue irradiation. Cancer Invest. 13: 8-15, 1995.
19. Pilepich M.V., Winter K., Roach M. et al.: Phase III Radiation Oncology Group (RTOG) trial 86-10 of androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate. Proc. Am. Soc. Clin. Oncol. 17: 308a (Abstr 1185), 1998.
20. Bubendorf L., Schopfer A., Wagner U. et al.: Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum. Pathol. 31: 578-583, 2000.
21. Sternberg C.: Hormone refractory metastatic prostate cancer. Ann. Oncol. 3: 331-335, 1992.
22. Scher H.I., Chung L.W.K.: Bone metastases: improving the therapeutic index. Semin. Oncol. 21: 630-656, 1994.
23. Trump D.L., Shipley W.U., Dillioglugil O., Scardino P.T.: Neoplasms of the prostate. In: Holland J.F., Bast R.C. Jr, Morton D.L., editors. Cancer medicine, 4th ed. Baltimore: Williams and Wilkins 2125-2164, 1997.
24. Rosendahl I., Kiebert G.M., Curran D. et al.: Quality-adjusted survival (Q-TWiST) analysis of EORTC trial 30853: comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer. Prostate 38: 100-109, 1999.
25. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomized trials with 3283 deaths in 5710 patients Lancet 346: 265-269, 1995.
26. Denis L.J., Carneiro de Moura J.L., Bono A. et al.: Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). Urology 42: 119-130, 1993.
27. Eisenberger M.A., Blumenstein B.A., Crawford E.D. et al.: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N. Engl. J. Med. 339: 1036-1042, 1998.
28. Schally A.V.: LHRH analogues: their impact on the control of tumorigenesis. Peptides 20: 1247-1262, 1999.
29. Sharifi R. and Soloway M.: Leuprolide Study Group: clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. J. Urol. 143: 68-72, 1990.
30. Zarandi M., Horvath J.E., Halmos G. et al.: Synthesis and biological activities of highly potent antagonist of growth hormone-releasing hormone. Proc. Natl. Acad. Sci. U.S.A. 91: 12298-12303, 1994.
31. Varga J.L., Schally A.V., Csernus V.J. et al.: Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities. Proc. Natl. Acad. Sci. U.S.A. 96: 692-697, 1999.
32. Crawford E.D., Eisenberger M.A., McLeod D.G. et al.: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med. 321: 419-424, 1989.
33. Gonzalez-Barcena B., Vadillo-Buenfil M., Cortez-Morales A. et al.: LHRH antagonist SB-75 (Cetrorelix) as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord. Urology 45: 275-281, 1995.
34. Labrie F., Dupont A., Belanger A., Lachance R.: Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist. J. Urol. 138: 804-806, 1987.
35. Prostate Cancer Trialists' Collaborative Group. Maximum adrogen blockade in advanced prostate Prostate Cancer Trialists cancer: an overview of the randomised trials. Lancet 355 (9214): 1491-1498, 2000.
36. Tomera K., Gleason D., Gittelman M. et al.: The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J. Urol. 165: 1585-1589, 2001.
37. Rambeaud J.J.: Intermittent complete androgen blockade in metastatic prostate cancer. Eur. Urol. 35 (Suppl 1): 32-36, 1999.
38. Taplin M.E., Bubley G.J., Shuster T.D. et al.: Mutation of the androgen receptor gene in metastatic androgen independent prostate cancer. N. Engl. J. Med. 332: 1393-1398, 1995.
39. Visakorpi T., Hyytinen E., Koivisto P. et al.: In vivo amplication of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 9: 401-405, 1995.
40. Bruchovsky N., Rennie P.S., Coldman A.J. et al.: Effects of androgen withdrawal on the stem cell composition of the shionogi carcinoma. Cancer Res. 50: 2275-2282, 1990.
41. Crawford E.D., Bennett C.L., Stone N.N. et al.: Comparison of perspectives on prostate cancer: analysis of survey data. Urology 50: 366-372, 1997.
42. Strum S.B., Scholz M.C., McDermed J.E.: Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy. Oncologist 5(1): 45-52, 2000.
43. Dawson N.A.: Intermittent androgen deprivation. Curr. Oncol. Rep. 2: 409-416, 2000.
44. Kelly W.K., Scher H.J.: Prostate specific antigen decline after antiandrogen withdrawal. The flutamide withdrawal syndrome. J. Urol. 149: 607-609, 1993.
45. Small E.J., Vogelzang N.J.: Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J. Clin. Oncol. 15: 382-388, 1997.
46. Scher H.I., Kelly W.K.: Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J. Clin. Oncol. 11: 1566-1572, 1993.
47. Akakura K., Bruchovsky N., Goldenberg S.L. et al.: Effects of intermittent androgen suppression on androgen dependanttumors. Cancer 71: 2782-2790, 1993.